# Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer

> **NCT02283372** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 30 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** nab-Paclitaxel
- **DRUG:** Gemcitabine
- **RADIATION:** Intensity modulated radiation

## Key facts

- **NCT ID:** NCT02283372
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-21
- **Primary completion:** 2018-05-14
- **Final completion:** 2019-04-18
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02283372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02283372, "Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02283372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*